Antioxidants
Phase 3Biologic
Antioxidants is one of 139 biologic programs targeting Adenoma. It is currently in Phase 3.
5
Indications
10
Total Trials
1
Active Trials
138
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
165 competitors in Atherosclerosis
#DrugCompanyPhaseTrials
1Avandia
Alnylam PharmaceuticalsPhase 3
Estrace
Novo NordiskPhase 3
Depo-Provera
PfizerPhase 3
Actemra
RochePhase 3
Colcrys
Alnylam PharmaceuticalsPhase 3
Glucotrol
PfizerPhase 3
Brilinta
AstraZenecaPhase 3
Ilaris
NovartisPhase 3
Benicar
CCosette Pharmaceuticals, Inc.
Phase 3
Altoprev
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Tobacco1 trial
Nevada Environmental Tobacco Smoke and Health Study
Completed·NNational Institute of Environmental Health Sciences (NIEHS)·Phase 3·NCT00046306·375 enrolled
Fibrosis1 trial
5 more indications
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Antioxidants. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 3[1]
- Company
- IInstitute of Child Health